🌎 Adherence is a major obstacle for patients with chronic conditions such as diabetes or hypertension. Over half of patients still struggle to stick to their treatments. 🤝 Let's work together to overcome these challenges. Join #AsOne by Servier to improve patient control and adherence for better patient care. 🔗 For more information about Servier, visit servier.com #ASONE #CMVD #CardiovascularDiseases #Diabetes #VenousDiseases
Servier
Fabrication de produits pharmaceutiques
Committed to therapeutic progress to serve patient needs
À propos
Fondé pour servir la santé, Servier est un groupe pharmaceutique international gouverné par une Fondation, qui aspire à avoir un impact sociétal significatif pour les patients et pour un monde durable. Son modèle unique de gouvernance lui permet de servir pleinement sa vocation avec une vision à long terme : être engagé pour le progrès thérapeutique au bénéfice des patients. Les 21 900 collaborateurs qui composent le Groupe sont engagés autour de cette vocation commune, source d’inspiration au quotidien. Leader mondial en cardiologie, Servier a pour ambition de devenir un acteur focalisé et innovant en oncologie en ciblant des cancers difficiles à traiter. C’est pourquoi le Groupe consacre plus de 70 % de son budget de R&D au développement de thérapies ciblées et innovantes en oncologie. Les neurosciences et les maladies immuno-inflammatoires constituent un futur relais de croissance. Dans ces domaines, Servier se focalise sur un nombre restreint de pathologies spécifiques dans lesquelles une caractérisation précise des patients permet de proposer une réponse thérapeutique ciblée, grâce à la médecine de précision. Pour favoriser l’accès à des soins de qualité pour tous, et à moindre coût, le Groupe propose également une offre de médicaments génériques couvrant la majorité des pathologies, en s’appuyant sur des marques fortes en France, en Europe de l’Est, au Brésil et au Nigeria. Dans tous ces domaines, le Groupe intègre la voix du patient à chaque étape du cycle de vie du médicament. Servier, dont le siège social est basé en France, s’appuie sur une solide implantation géographique dans plus de 150 pays et a réalisé, en 2023, un chiffre d’affaires de 5,3 milliards d’euros. --- Si vous avez constaté ou si vous pensez être sujet à un problème de santé lié à l’utilisation d’un médicament Servier ou de tout autre produit de santé Servier, rendez-vous sur servier.com
- Site web
-
https://servier.com
Lien externe pour Servier
- Secteur
- Fabrication de produits pharmaceutiques
- Taille de l’entreprise
- + de 10 000 employés
- Siège social
- Suresnes
- Type
- Société civile/Société commerciale/Autres types de sociétés
Lieux
-
Principal
50 rue Carnot
92150 Suresnes, FR
Employés chez Servier
Nouvelles
-
🔍 #DYK? Our latest podcast, "The Patient’s Side of the Story," was made in collaboration with the Saclay Research & Development Patient Board. Some of the board members share their own personal disease journeys. 🔬The Saclay Research & Development Patient Board plays a crucial role in incorporating patient perspectives in our R&D processes. You can listen to all the episodes in the first issue of Insights by Servier, our digital magazine 👉 https://lnkd.in/eypNJ3XQ #WeAreServier #InsightsByServier #PatientsBoard
Ce contenu n’est pas disponible ici
Accédez à ce contenu et plus encore dans l’application LinkedIn
-
#SAVETHEDATE 🗓️ Organized by HealthTech For Care, the HealthTech Innovation Days (HTID®) will take place on September 17 - 18. This event aims to foster new industrial partnerships and investments in biotechs to accelerate the development of and accessibility to new treatments for patients. That is why we have actively 💪 supported #HTID since its very first edition. Don’t miss this opportunity to connect, collaborate, and contribute to the evolution of healthcare. 👉 Pre-register now https://lnkd.in/e7ZP-ZCv See you there! Let's shape the future of healthcare together. #HTID6 #innovation #biotech #Medtech
-
-
🗣️ “The often lengthy and costly phenomenon of the diagnostic odyssey is a major burden for patients and health care systems around the world. I believe, however, that solutions do exist to reduce the time spent in diagnostic drift!” Nicolas Garnier, Chief Patient Officer at Servier, shares his views on the challenges involved in the diagnostic odyssey, a distressing ordeal for patients. Read more at servier.com 👉 https://lnkd.in/emv5fChR #patient #adherence #health #WeAreServier #MovedByYou
-
-
Servier a republié ceci
#HealthData is a major catalyst for driving the discovery of innovative therapies. Access to health data is therefore vital to facilitate research and improve patient outcomes. The #EHDS will require the public and private sectors to work together in new and innovative ways. We look forward to working with the EU institutions and Member States to address critical aspects that require further clarification within the implementation phase. Find out more about our position on the Regulation on the European Health Data Space: https://lnkd.in/dfxBTPhB #WeWontRest
-
🌎 At least 1.4 billion people worldwide suffer from hypertension; add to these others who are affected by cardiometabolic and venous diseases, with many experiencing multiple conditions simultaneously. 💡 In fact, there are: - 1.4 billion with hypertension. - 600 million with dyslipidemia. - 537 million with diabetes. - 100 million with chronic coronary syndrome. - Around 67 million with heart failure. Many individuals are affected by 2 or more of these conditions, highlighting the complex nature of cardiometabolic and venous diseases. 🤝 At Servier, we have united our products and tailored services under 1 portfolio to help you improve patient care. Let's unite #AsOne; because together, we're stronger. 🔗 For more information about Servier, visit servier.com #ASONE #CMVD #CardiovascularDiseases #Diabetes #VenousDiseases
-
-
🔬 Innovation is mandatory in the field of Research and Development. At Servier, we believe that biotech start-ups are major players in innovation and that their work must be supported. 💬 Listen to Andrew Rudd, CEO and Co-Founder of Palm Therapeutics, share the innovation they’re working on, which will be a game changer in cancer R&D. Find the entire article in the latest issue of Insights by Servier 👉 https://lnkd.in/gmvpqRcg #WeAreServier #InsightsByServier #StartUp California Life Sciences (CLS)
-
-
For several years, we have been committed to treating chronic venous disease, partnering with health care professionals 👩⚕️🧑⚕️. Venous disease is one of the most common diseases. Varicose veins are present in 25%-33% of female and 10%-40% of male adults. This summer, we’re back 🚀🔥 with a new season of our awareness campaign. Are you ready to be onboard in this Final Call for chronic venous disease? Help us 🗣️ spread the word and share our Facebook and Instagram campaigns? Check our final call video and visit our chronic venous disease section 👉 https://lnkd.in/ecKCRE4F #ChronicVenousDisease #CVD #WeAreServier #MovedByYou
-
🚨 In patients with dyslipidemia, 64% have hypertension and 25% have diabetes. Among these patients, 25.6% have uncontrolled hypertension and 23% have uncontrolled diabetes. 🌐 Tackling these interconnected health issues is essential for improving global health outcomes. Let's work together toward better management and prevention! 🤝 At Servier, we adhere to a holistic approach in treating cardiometabolic and venous diseases (CMVD). Let's be #AsOne for better patient outcomes and tailored solutions. 🔗 For more information, visit servier.com #ASONE #CMVD #CardiovascularDiseases #Diabetes #VenousDiseases
-
-
🚨 At the beginning of the summer, we proposed a challenge to our employees: to take 1 billion steps 🏃♀️🏃♂️ for the Serious Fun association, in order to finance the medical stay of several children suffering from cancer. 🔥🚀 The challenge was met! Over 3,000 employees took part, 79 teams were formed and over 1 billion steps were taken! Congratulations 👏 to all our employees, who are committed to improving patients’ lives! #commitment #patient #WeAreServier #MovedByYou
-